Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis
P Rogliani, L Calzetta, F Cavalli, MG Matera… - Pulmonary …, 2016 - Elsevier
Background The prevalence of idiopathic pulmonary fibrosis (IPF) is increasing every year.
Pirfenidone and nintedanib were approved for treatment of IPF in 2014, but they received …
Pirfenidone and nintedanib were approved for treatment of IPF in 2014, but they received …
Therapy for idiopathic pulmonary fibrosis: lessons from pooled data analyses
In 2014, two landmark clinical trials (ASCEND and INPULSIS) were published
demonstrating, for the first time, a treatment benefit for patients with idiopathic pulmonary …
demonstrating, for the first time, a treatment benefit for patients with idiopathic pulmonary …
[PDF][PDF] OFEV®(Nintedanib)
FV Mittlere - Respiration, 2015 - karger.com
97 | 6 | 19 Page 1 Respiration print ISSN 0025–7931 online e-ISSN 1423–0356 www.karger.com/res
EABIP International Journal of Thoracic Medicine S. Karger Medical and Scientific …
EABIP International Journal of Thoracic Medicine S. Karger Medical and Scientific …